VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN® (Pelareorep) in Combination With Lenalidomide or Pomalidomide

Trial Profile

VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN® (Pelareorep) in Combination With Lenalidomide or Pomalidomide

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Pelareorep (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms MUK eleven; VIRel
  • Most Recent Events

    • 14 Sep 2017 According to an Oncolytics Biotech media release, preliminary data are expected to be available in the first quarter of 2018.
    • 14 Sep 2017 According to an Oncolytics Biotech media release, The trial, run through the Myeloma UK Clinical Trial Network (CTN) in collaboration with charity Myeloma UK, the University of Leeds.
    • 14 Sep 2017 According to an Oncolytics Biotech media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top